Xaira Therapeutics valuation, funding and investors
Xaira Therapeutics works in AI-Driven drug discovery and development, based in South San Francisco, United States. Founded in 2023, it has about 212 employees.
- Last round
- Growth · $1.00B · Apr 2024
- Valuation at last round
- $11.11B · implied
- Headcount
- 212 · up
- Grade
- C
- Founded
- 2023
Xaira Therapeutics valuation today
VCMC values Xaira Therapeutics at $15.2B today, with a range of $4.9B to $23.1B and a grade of C. The valuation starts from its last funding round, a growth round in Apr 2024.
Valuation by date (48 rows)
Each point is what the model would have shown on that date, using only what was known then; before its first round, a company is valued as a startup because it later raised.
| Date | Valuation | Range | Predicted in 1 yr | Phase | Headcount | Trend | Grade | Winding-down probability |
|---|---|---|---|---|---|---|---|---|
| 1 Jan 2023 | $20.8M | $7.56M – $57.0M | $22.7M (+9%) | before first round | – | unknown | D | 0% |
| 1 Feb 2023 | $20.9M | $7.62M – $57.5M | $22.8M (+9%) | before first round | – | unknown | D | 0% |
| 1 Mar 2023 | $21.1M | $7.67M – $57.9M | $23.0M (+9%) | before first round | – | unknown | D | 0% |
| 1 Apr 2023 | $21.2M | $7.73M – $58.3M | $23.2M (+9%) | before first round | – | unknown | D | 0% |
| 1 May 2023 | $21.4M | $7.78M – $58.7M | $23.3M (+9%) | before first round | – | unknown | D | 0% |
| 1 Jun 2023 | $21.5M | $7.84M – $59.2M | $23.5M (+9%) | before first round | – | unknown | D | 0% |
| 1 Jul 2023 | $21.7M | $7.90M – $59.6M | $23.7M (+9%) | before first round | – | unknown | D | 0% |
| 1 Aug 2023 | $21.9M | $7.96M – $60.0M | $23.7M (+8%) | before first round | – | unknown | D | 0% |
| 1 Sep 2023 | $22.0M | $8.02M – $60.5M | $23.7M (+8%) | before first round | – | unknown | D | 0% |
| 1 Oct 2023 | $22.2M | $8.07M – $60.9M | $23.7M (+7%) | before first round | – | unknown | D | 0% |
| 1 Nov 2023 | $22.3M | $8.13M – $61.4M | $23.7M (+6%) | before first round | – | unknown | D | 0% |
| 1 Dec 2023 | $22.5M | $8.19M – $61.8M | $23.7M (+5%) | before first round | – | unknown | D | 0% |
| 1 Jan 2024 | $22.7M | $8.26M – $62.3M | $23.7M (+5%) | before first round | – | unknown | D | 0% |
| 1 Feb 2024 | $22.8M | $8.32M – $62.8M | $23.7M (+4%) | before first round | – | unknown | D | 0% |
| 1 Mar 2024 | $23.0M | $8.38M – $63.2M | $23.7M (+3%) | before first round | – | unknown | D | 0% |
| 1 Apr 2024 | $23.2M | $8.44M – $63.7M | $23.7M (+2%) | before first round | – | unknown | D | 0% |
| 24 Apr 2024 | $11.1B | $7.3B – $18.6B | $12.2B (+10%) | after a round | – | unknown | B | 0% |
| 1 May 2024 | $11.1B | $7.3B – $18.6B | $12.2B (+10%) | after a round | – | unknown | B | 0% |
| 1 Jun 2024 | $11.2B | $7.3B – $18.6B | $12.2B (+9%) | after a round | – | unknown | B | 0% |
| 1 Jul 2024 | $11.3B | $7.3B – $18.6B | $12.2B (+8%) | after a round | – | unknown | B | 0% |
| 1 Aug 2024 | $11.4B | $7.3B – $18.6B | $12.2B (+7%) | after a round | 79 | unknown | B | 0% |
| 1 Sep 2024 | $11.5B | $7.3B – $18.6B | $12.2B (+6%) | after a round | 79 | flat | B | 0% |
| 1 Oct 2024 | $11.6B | $7.3B – $18.6B | $12.2B (+5%) | after a round | 79 | flat | B | 0% |
| 1 Nov 2024 | $11.7B | $7.3B – $18.6B | $12.2B (+5%) | after a round | 79 | flat | B | 0% |
| 1 Dec 2024 | $12.5B | $8.0B – $20.4B | $13.4B (+8%) | after a round | 120 | growing | B | 0% |
| 1 Jan 2025 | $12.7B | $8.0B – $20.4B | $13.4B (+6%) | after a round | 120 | growing | B | 0% |
| 1 Feb 2025 | $13.0B | $8.1B – $20.8B | $13.6B (+5%) | after a round | 130 | growing | B | 0% |
| 1 Mar 2025 | $13.2B | $8.1B – $20.8B | $13.6B (+3%) | after a round | 130 | growing | B | 0% |
| 1 Apr 2025 | $13.5B | $8.1B – $20.8B | $13.6B (+1%) | after a round | 130 | growing | B | 0% |
| 1 May 2025 | $13.6B | $8.1B – $20.8B | $13.6B (0%) | after a round | 130 | growing | B | 0% |
| 1 Jun 2025 | $13.6B | $8.1B – $20.8B | $13.6B (0%) | after a round | 130 | growing | B | 0% |
| 1 Jul 2025 | $13.6B | $8.0B – $20.8B | $13.6B (0%) | after a round | 130 | growing | B | 0% |
| 1 Aug 2025 | $13.6B | $7.9B – $20.8B | $13.6B (0%) | after a round | 130 | growing | B | 0% |
| 1 Sep 2025 | $14.5B | $8.4B – $22.1B | $14.5B (0%) | after a round | 174 | growing | B | 0% |
| 1 Oct 2025 | $14.5B | $8.3B – $22.1B | $14.5B (0%) | after a round | 174 | growing | B | 0% |
| 1 Nov 2025 | $14.5B | $8.3B – $22.1B | $14.5B (0%) | after a round | 174 | growing | B | 0% |
| 1 Dec 2025 | $14.7B | $8.3B – $22.4B | $14.7B (0%) | after a round | 183 | growing | B | 0% |
| 1 Jan 2026 | $14.7B | $8.2B – $22.4B | $14.7B (0%) | after a round | 183 | growing | B | 0% |
| 1 Feb 2026 | $14.7B | $8.2B – $22.4B | $14.7B (0%) | after a round | 183 | growing | B | 0% |
| 1 Mar 2026 | $14.7B | $8.1B – $22.4B | $14.7B (0%) | after a round | 183 | growing | B | 0% |
| 1 Apr 2026 | $14.8B | $8.1B – $22.6B | $14.8B (0%) | after a round | 191 | growing | B | 0% |
| 1 May 2026 | $14.8B | $7.7B – $22.6B | $14.8B (0%) | after a round | 191 | growing | B | 0% |
| 1 Jun 2026 | $15.0B | $7.7B – $22.9B | $15.0B (0%) | after a round | 203 | growing | B | 0% |
| 1 Jul 2026 | $15.0B | $7.6B – $22.9B | $15.0B (0%) | after a round | 203 | growing | B | 0% |
| 1 Aug 2026 | $15.0B | $5.4B – $22.9B | $14.8B (-1%) | after a round | 203 | up | C | 0% |
| 1 Sep 2026 | $15.0B | $5.2B – $22.9B | $14.8B (-2%) | after a round | 203 | up | C | 0% |
| 1 Oct 2026 | $15.2B | $5.1B – $23.1B | $15.0B (-1%) | after a round | 212 | up | C | 0% |
| 24 Oct 2026 | $15.2B | $4.9B – $23.1B | $9.1B (-40%) | after a round | 212 | up | C | 0% |
Key facts about Xaira Therapeutics
- Founded
- 2023
- Headquarters
- South San Francisco, United States
- Employees
- about 212 +22% in a year
- Total raised
- $1.00B
- Funding rounds
- 1
- Last round
- Growth Equity Apr 2024
Xaira Therapeutics was founded in 2023 by David Baker, Hetu Kamisetty, Marc Tessier-Lavigne and Vikram Bajaj.
Xaira Therapeutics funding history
Xaira Therapeutics has 1 funding round on record, from Apr 2024 to Apr 2024, $1.00B in total. None disclosed a valuation.
Growth Equity 23 Apr 2024
Led by ARCH Venture Partners, Foresite Capital; with F-Prime Capital, New Enterprise Associates, Sequoia Capital, Lux Capital, Lightspeed Venture Partners, Menlo Ventures, Two Sigma Ventures, Parker Institute for Cancer Immunotherapy, Byers Capital, RSquared VC, SV Angel.
Sources: biotechgate.com, fiercebiotech.com, techcrunch.com and 4 more
$1.00B
Xaira Therapeutics investors
13 investors have backed Xaira Therapeutics; ARCH Venture Partners and Foresite Capital led at least one round.
- ARCH Venture Partners lead
- Lightspeed Venture Partners
- Lux Capital
- Menlo Ventures
- New Enterprise Associates
- Parker Institute for Cancer Immunotherapy
- Sequoia Capital
- SV Angel
- Two Sigma Ventures
What Xaira Therapeutics does
Xaira Therapeutics works in biotechnology, with 14 recorded offerings and customers in pharmaceuticals and biotechnology.
Xaira Therapeutics, Inc. is an American biotechnology company engaged in the discovery and development of medicines using artificial intelligence and computational methods. The company focuses on drug discovery and development, integrating machine learning, data science, and multi-omic analysis to advance scientific understanding and therapeutic product development. Xaira Therapeutics also provides computational platforms and data sets for drug discovery and operates as a provider of AI-driven solutions for the pharmaceutical industry.
Description from Veridion's company data.
Products and services
- AI-Driven Drug Discovery and Development
- Computational Drug Design and Engineering
- Machine Learning Solutions for Biological Modeling
- Multi-Omic Data Generation and Analysis
- Therapeutic Product Development
- Protein Design and Engineering
- Biomedical Data Science Services
- AI Platform Development for Drug Research
- Scientific Process Automation for Drug Development
- Disease-Specific Therapeutic Research
- Pharmaceutical Research and Development Services
- AI-Enabled Therapeutic Product Development
- Biological Process Optimization for Drug Engineering
- Data-Driven Drug Candidate Selection Services
Markets
- Pharmaceuticals
- Biotechnology
Technology
- AI-Driven Drug Discovery
- Machine Learning for Biological Understanding
- Multi-Omic Data Integration
Business model
- Business-to-Business
- Manufacturing
- Enterprise
Industry codes (NAICS)
- 541714 Research and Development in Biotechnology (except Nanobiotechnology) 100% match
Questions about Xaira Therapeutics
What is Xaira Therapeutics worth?
Valuation $15.2B (range $4.9B to $23.1B), as of 24 Oct 2026.
Has Xaira Therapeutics raised money?
Xaira Therapeutics has 1 funding round on record, from Apr 2024 to Apr 2024, $1.00B in total. None disclosed a valuation.
Who has invested in Xaira Therapeutics?
ARCH Venture Partners, Foresite Capital, Byers Capital, F-Prime Capital, Lightspeed Venture Partners and Lux Capital, and 7 more. Lead investors include ARCH Venture Partners and Foresite Capital.
How many people work at Xaira Therapeutics?
About 212, up 22% over the last year. Headcount grew from 79 in Jul 2024 to 212 in Sep 2026.
What does Xaira Therapeutics do?
Xaira Therapeutics works in biotechnology, with 14 recorded offerings and customers in pharmaceuticals and biotechnology. Its main offerings are AI-Driven drug discovery and development, computational drug design and engineering and machine learning solutions for biological modeling.
When was Xaira Therapeutics founded, and where is it based?
Xaira Therapeutics was founded in 2023 and is based in South San Francisco, United States. It has about 212 employees, up 22% over the last year.